What Tilidin comp.-CT treats: Main Uses and Benefits

The Tilidine/Naloxone fixed-dose combination is generally utilized in advanced analgesic protocols to manage significant levels of discomfort. It is considered relevant for symptom patterns that require additional support for symptom management, which may assist with maintaining functional stability. These formulations are utilized in conditions characterized by periods of heightened symptoms requiring sustained supportive management.

This medication is commonly used to help with symptoms related to physical discomfort when the intensity is classified as moderate to severe. It plays a role in managing symptoms across several therapeutic areas, including conditions presenting with systemic or localized discomfort (such as chronic pain), conditions associated with acute or disruptive episodes (such as postoperative pain), and symptoms of increased neurological or muscular activity.

The primary therapeutic benefit is to offer symptomatic relief that helps patients cope more steadily with challenging symptom manifestations, particularly when discomfort is unresponsive to standard, non-opioid pain relievers.

---

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning This medication is generally used to address pain symptoms that have progressed in severity to the moderate-to-severe range, supporting functional stability in patients who require sustained symptomatic assistance.

Who Must Not Use Tilidin comp.-CT (Contraindications)

Use of this medicine is strictly contraindicated in several population groups, as defined by regulatory labeling. This includes individuals with an established Opioid Drug Dependence, as the Naloxone component will immediately precipitate an acute withdrawal syndrome. Use is also prohibited for patients with known Hypersensitivity to Tilidine, Naloxone, or any other excipients. The specific metabolic disorder Porphyria also defines non-eligibility and contraindicates use.

---

Population Restrictions and Use with Caution

The medicine is generally intended for Adults and Adolescents aged 14 years and older. Use is not recommended for children younger than 14 years due to insufficient clinical experience.

Conditional use applies to specific groups:

• Hepatic Function: Patients with Pronounced Hepatic Impairment must use the medicine with particular caution.
• Substance History: Individuals with a history of other dependence disorders (e.g., drug or alcohol addiction) require careful monitoring.
• Pregnancy/Lactation: Use during Pregnancy is generally not recommended or only permitted after a strict benefit-risk assessment. Breastfeeding must be interrupted if treatment is absolutely necessary.
• Renal Function: No standard dose adjustment is required for patients with Impaired Kidney Function (renal impairment).

Tilidin comp.-CT Interactions with other medicines and products

It is essential to inform your doctor or pharmacist about all prescription and non-prescription medicines, supplements, or herbal products you are currently taking before starting treatment with Tilidin comp.-CT. This medication contains tilidine (an opioid) and naloxone (an opioid antagonist), and concurrent use with certain substances can lead to serious drug interactions, including enhanced central nervous system (CNS) depression or altered metabolism.

---

Increased Risk of Sedation and Respiratory Depression

Concurrent use with other CNS depressants increases the risk of severe side effects such as deep sedation, respiratory depression (slowed or shallow breathing), coma, and even death. This critical interaction may occur with:

• Other opioids (even for cough or pain).
• Sedative medications (e.g., benzodiazepines, barbiturates).
• Hypnotics (sleeping pills).
• Alcohol.
• Certain antidepressants, antihistamines, or muscle relaxants.

---

Metabolic and Serotonin-related Interactions

Tilidine is metabolized in the liver by specific enzymes (primarily CYP3A4 and CYP2C19) to its active pain-relieving substance, nortilidine. Drugs that inhibit these enzymes (e.g., certain antifungal agents like voriconazole) can significantly alter the concentration of tilidine and its active metabolite, potentially increasing the risk of adverse effects. Conversely, inducers of these enzymes may reduce the effectiveness of Tilidin comp.-CT.

Combining Tilidin comp.-CT with serotonergic drugs (e.g., certain antidepressants like MAOIs, SSRIs, SNRIs, or triptans) may precipitate Serotonin Syndrome, a potentially life-threatening condition characterized by mental status changes, autonomic instability, and neuromuscular abnormalities.

Activating Central mu-Opioid Receptors and Descending Inhibition

The drug's action begins when Tilidine, a prodrug, is metabolized into the active substance, Nortilidine. Nortilidine acts as an agonist at mu-opioid receptors (mu-OR) in the central nervous system (CNS). Activation of these receptors suppresses the release of excitatory neurotransmitters in ascending nociceptive pathways, thereby reducing the transmission of pain signals to the brain. Simultaneously, Nortilidine acts as a weak dual inhibitor of norepinephrine (NE) and serotonin (5-HT) reuptake. By increasing the synaptic concentration of these monoamines, this mechanism enhances the activity of the body's natural descending inhibitory pathway, further modulating the intensity of the physiological response to nociceptive stimuli.

Pharmacokinetic Constraint by Naloxone

The co-formulated component, Naloxone, is a potent mu-opioid receptor antagonist. When the medicine is taken orally, Naloxone undergoes extensive first-pass deactivation in the liver, allowing the Nortilidine mechanism to proceed unopposed. If the oral route is bypassed, high concentrations of Naloxone act as a competitive antagonist, preventing Nortilidine from binding to and activating the mu-opioid receptor.

Official Administration Guidelines

Tilidin comp.-CT is a fixed-dose combination authorized for oral administration. The administration schedule is designed to ensure the abuse-deterrent system, based on the inclusion of naloxone, remains intact and functional via the oral route.

---

Dosing and Scheduling

The medicine is supplied in prolonged-release tablets and an oral solution. The standard adult dosing regimen is highly individualized but is aligned with established clinical guidelines:

• Starting Dose and Regimen: The initial dose for prolonged-release tablets often begins at 50 mg of Tilidine (with 4 mg Naloxone), administered twice daily. The tablets are typically taken at regular 12-hour intervals to maintain constant drug levels, supporting a fixed, time-contingent schedule for chronic pain management.
• Dose Titration: Dosage may be adjusted individually across various strengths (50 mg/4 mg to 200 mg/16 mg) based on the patient's requirement. The maximum recommended dose in long-term treatment is 600 mg of Tilidine per day.
• Oral Solution Use: The immediate-release oral solution may be used up to six times daily when appropriate for dosing flexibility or acute needs.

---

Administration Specifics and Special Populations

For the prolonged-release tablets, the official instruction requires the tablet to be swallowed whole. The integrity of the tablet must be preserved to ensure the release mechanism and the abuse-deterrent feature function as intended.

• Hepatic Adjustment: Use is generally cautioned in the presence of severe hepatic impairment due to the drug's dependence on liver metabolism for activation.
• Pediatric Guidelines: A single dose guideline for pediatric patients is 0.5 mg/kg body weight.

Research evidence / Overview of studies for Tilidin comp.-CT

Evidence for Use in Chronic Moderate to Severe Pain

Research exploring the use of this medicine for ongoing, chronic pain of moderate to severe intensity has been conducted primarily in adult populations. The evidence base includes long-term observational multicenter studies and systematic reviews.

Researchers explored outcomes related to physical discomfort by monitoring pain intensity scores and how these correlated with measures of functional stability, such as the impact on daily activity and sleep. The research describes the patterns observed in the studies over time, focusing on whether initial measured changes were sustained. Data for certain groups remain insufficient, and the long-term findings rely heavily on observational settings, suggesting that the certainty of findings is limited regarding the absolute functional outcomes.

---

Research on Acute Pain Relief

Research on the components' influence on acute pain was conducted using short-term, single-dose Randomized Controlled Trials (RCTs) and controlled experimental pain models. The research examined outcomes describing episodic changes, primarily focusing on the timeframe for the onset of change in pain measurement. Studies describe that the active component was observed to influence these pain measurements in a short timeframe.

These controlled studies mainly describe the observed physiological influence of the components on pain signals. Follow-up durations were limited, typically lasting only hours or days. The studies provide limited information regarding the research base for complex clinical acute pain.

---

Study Quality and Known Research Gaps

The evidence for the Tilidine/Naloxone combination is supported by RCTs for its short-term capacity, which are considered to provide a high level of research certainty for that specific measure. For chronic pain, the evidence level is moderate, relying on extensive long-term observational data. A key limitation is the inherent difference between trial findings and real-world outcomes: findings describe group patterns, not personal outcomes. Furthermore, comparative evidence is lacking for many long-term measures, and limited information is available specifically for older adults or individuals with severe impairment of organs responsible for metabolizing the medicine.

Common questions about Tilidin comp.-CT (FAQ)

Q: What is Tilidin comp.-CT used for?

A: Tilidin comp.-CT is a pain reliever used to treat moderate to severe pain.

Q: What are the active ingredients in Tilidin comp.-CT?

A: The active ingredients are tilidine and naloxone.

Q: How does tilidine work to relieve pain?

A: Tilidine is an opioid analgesic. It works in the central nervous system to change how the body feels and responds to pain.

Q: What is the purpose of naloxone in this combination?

A: Naloxone is included to prevent the misuse of the medication. If the tablets are taken as prescribed, the naloxone component is mostly broken down and has no effect. However, if the medication is misused by dissolving and injecting it, naloxone prevents the euphoric effects of tilidine.

Q: How should I take Tilidin comp.-CT tablets?

A: The tablets should be swallowed whole with a sufficient amount of liquid, regardless of meals. Do not crush or chew the tablets.

Q: What are some common side effects of Tilidin comp.-CT?

A: Common side effects may include nausea, vomiting, dizziness, and drowsiness. Always consult the official package leaflet for a complete list of side effects.

Q: Can I drink alcohol while taking Tilidin comp.-CT?

A: No, alcohol should be avoided while taking this medication. Alcohol can increase the sedative effects of tilidine and may increase the risk of serious side effects, including breathing difficulties.

Q: Is Tilidin comp.-CT addictive?

A: As an opioid-containing medicine, tilidine has the potential for dependence and addiction. Taking the medication only as prescribed and for the shortest necessary duration can help minimize this risk. Consult your healthcare provider about any concerns regarding dependence.

Q: What should I do if I miss a dose?

A: If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. Contact your healthcare provider for specific advice.

Q: What should I do in case of an overdose?

A: If you suspect an overdose, seek immediate medical attention or contact an emergency service right away. Signs of overdose can include severe drowsiness, slowed or shallow breathing, or extreme dizziness.

Official Regulatory Storage and Disposal Requirements

Official regulatory documents strictly define the conditions under which Tilidin comp.-CT must be stored to maintain its stability and effectiveness.

Storage Requirement	Official Statement
Temperature	Do not store above 30 °C.
Protection	Keep in the original package to protect from light and moisture.
Handling	Do not freeze.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal must comply with official pharmaceutical waste guidelines. Do not dispose of unused or expired Tilidin comp.-CT in household waste or via wastewater. For proper disposal, the medicine must be returned to a pharmacy or a designated drug take-back point.